Stephan Henschen

ORCID: 0000-0003-0880-9130
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Breast Cancer Treatment Studies
  • Estrogen and related hormone effects
  • HER2/EGFR in Cancer Research
  • Advanced Breast Cancer Therapies
  • Cancer Treatment and Pharmacology
  • Monoclonal and Polyclonal Antibodies Research
  • Complementary and Alternative Medicine Studies
  • Hemodynamic Monitoring and Therapy
  • Preterm Birth and Chorioamnionitis
  • Pregnancy-related medical research
  • Medical History and Research
  • Assisted Reproductive Technology and Twin Pregnancy
  • Cancer Genomics and Diagnostics
  • Medical and Health Sciences Research
  • BRCA gene mutations in cancer
  • Health and Medical Studies
  • Pregnancy and preeclampsia studies
  • Biomedical and Chemical Research
  • Radiomics and Machine Learning in Medical Imaging
  • Body Image and Dysmorphia Studies
  • Pericarditis and Cardiac Tamponade
  • Nutrition, Genetics, and Disease
  • Endometrial and Cervical Cancer Treatments
  • Breast Lesions and Carcinomas
  • Trauma, Hemostasis, Coagulopathy, Resuscitation

Helios Hospital Schwerin
2015-2022

MSH Medical School Hamburg – University of Applied Sciences and Medical University
2021

Helios Kliniken
2020

Die Johanniter
2010-2019

Comprehensive Cancer Center Erlangen
2016

Universitätsklinikum Erlangen
2016

Friedrich-Alexander-Universität Erlangen-Nürnberg
2016

Johanniter-Krankenhaus Bonn
2007-2016

Hochschule Hannover
2011

Federal Highway and Transport Research Institute
2011

FIFTH PART: APHASIA, AMUSIA AND AKALKULIA Henschen relates that on Feb. 28, 1912, the date of his sixty-fifth birthday, he was obliged by statute age limitation to retire as director medical clinic Stockholm, and thereby from usual clinical laboratory activities. This outlook not promising for original work in brain research, future investigations depended a review personal, anatomic material subject literature. However, undismayed after different publications disease heart (1913), auditory...

10.1001/archneurpsyc.1925.02200080073006 article EN Archives of Neurology And Psychiatry 1925-02-01

10.1007/bf01853525 article DE Graefe s Archive for Clinical and Experimental Ophthalmology 1926-09-01

Fulvestrant, the first-in-class selective estrogen receptor (ER) degrader (SERD), is clinically effective in patients with ER+ breast cancer, but it has administration and pharmacokinetic limitations. Pharmacodynamic data suggest complete ER degradation not achieved at fulvestrant's feasible dose. This presurgical study (NCT03236974) compared pharmacodynamic effects of fulvestrant AZD9496, a novel, orally bioavailable, nonsteroidal, potent SERD, treatment-naïve HER2- primary cancer awaiting...

10.1158/1078-0432.ccr-19-3387 article EN Clinical Cancer Research 2020-03-31

10.1007/bf02124904 article DE Graefe s Archive for Clinical and Experimental Ophthalmology 1911-01-01

10.1007/bf01814560 article DE Archiv für Psychiatrie und Nervenkrankheiten 1925-12-01

10.1007/bf02124903 article DE Graefe s Archive for Clinical and Experimental Ophthalmology 1911-01-01
Alexios Matikas Volker Möbus Richard Greil Anne Andersson Günther Steger and 95 more Michael Untch Tommy� Fornander Per Malmström Sabine Schmatloch Hemming Johansson Mats Hellström Yvonne Brandberg Michael Gnant Sibylle Loibl Theodoros Foukakis Jonas Bergh Niklas Lohman Martin Söderberg Per‐Uno Malmström Zakaria Einbeigi Per Karlsson Barbro Linderholm Stig Holmberg Lotta Dabrosin Elham Hedayati Kenneth Villman Sam Rotstein Birgitta Wallberg Tommy� Fornander Henrik Lindman Johan Ahlgren Per Edlund Lena Carlsson Nils‐Olof Bengtsson Eva Karlsson Sabine Schmatloch Matthias Kögel A. Kohls Eva‐Maria Grischke Gerold Baake G. W. Hoffmann Maria Dietrich Volker Möbus Ralf Adrion Volker Heyl Benjamin Schnappauf Thomas Göhler Gabriele Ziemendorff I. Thalmann Claudia Schumacher Erich Weiß Oliver Tomé Wolfgang Bauer Angelika Ober Andeas Schneeweiss H.‐G. Höffkes Helmut Forstbauer Erich-Franz Solomayer Doris Augustin Holger Schultz B Adhami Michael Niedermeier Hans Ulrich Ulmer Andrea Hocke M. Kusche Reinhard Hackenberg Andreas Roßmann Tilmann Lantzsch Jürgen Schulze‐Tollert Christoph Lerchenmüller Ekkehart Ladda Elke Wierick H.W. Tessen Gerd Raudies Alexandra Sallmann Berhardt Martin Christoph Uleer Kristina Lübbe R. Felberbaum W. Wiest Marc Sütterlin Christoph Thomssen Uwe-Jochen Göhring Hans Tesch Axel Gatzweiler Wolfgang Janni Marcus Schmidt Andeas Werner Lelia Bauer Agustinus Tulusan Tjong-Won Park Michael Berghorn Thomas Noesselt Stephan Henschen Herbert Stöger Christian Marth Angelika Pichler Michael Fridrik Vincent V. St. Omer Alois Lang

JCO

10.1200/jco.24.00178 article EN Journal of Clinical Oncology 2024-07-17

10.1007/bf01674215 article SV Journal of Neurology 1926-07-01

10.1111/j.1600-0447.1931.tb09515.x article DE Acta Psychiatrica Scandinavica 1931-09-01

<b>Introduction:</b> The EvaluateTM study (Evaluation of therapy management and patient compliance in postmenopausal hormone receptor-positive breast cancer patients receiving letrozole treatment) is a prospective, non-interventional for the assessment routine care women with invasive letrozole. parameters inclusion are presented discussed here. <b>Material Methods:</b> Between January 2008 December 2009 total 5045 310 centers were recruited to study. Inclusion criteria adjuvant treatment or...

10.1055/s-0034-1383401 article EN other-oa Geburtshilfe und Frauenheilkunde 2014-12-23

Summary The validity and reliability of plasma volume estimation using indocyanine green were investigated in five vitro experiments three vivo series. measurements reflected real volumes with an error about 1%. Comparative the same patients or Cr 51 labelled red cells differed by 1.7% (r = 0.97). mean (SD) difference between two successive was 38 (43) ml 0.99). Plasma measured before 7 min after a hyperosmolar saline bolus (100 ml, 1 molar) increased 223 (102) 286 (49) when determined...

10.1111/j.1365-2044.1993.tb06789.x article EN Anaesthesia 1993-01-01

&lt;b&gt;&lt;i&gt;Background:&lt;/i&gt;&lt;/b&gt; Decision-making for or against neoadjuvant adjuvant chemotherapy in postmenopausal patients with hormone receptor-positive breast cancer does not follow any clear guidelines, and some may unnecessarily undergo be exposed to the associated toxicity. The aim of this study was identify patient population whom issue bear relevance. &lt;b&gt;&lt;i&gt;Methods:&lt;/i&gt;&lt;/b&gt; Patients being treated letrozole prospective multicenter...

10.1159/000452468 article EN Breast Care 2016-01-01

Treatment of postmenopausal, hormone receptor-positive metastatic breast cancer (MBC) patients varies despite clear therapy guidelines, favoring endocrine treatment (ET). Aim this study was to analyze persistence palliative aromatase inhibitor (AI) monotherapy in MBC patients. EvAluate-TM is a prospective, multicenter, noninterventional evaluate with letrozole postmenopausal women receptor–positive cancer. To assess persistence, defined as the time from start end (TTEOT), two pre-specified...

10.1186/s12885-019-5806-y article EN cc-by BMC Cancer 2019-06-21

The classic mid-trimester preterm premature rupture of membranes (PPROM) is defined as a the fetal prior to 28 weeks gestation (WG) with oligo/anhydramnion; it complicates approximately 0.4-0.7% all pregnancies and associated very high neonatal mortality morbidity. Antibiotics have limited success prevent bacterial growth, chorioamnionitis inflammation. repetitive amnioinfusion does not work because fluid lost immediately after intervention. continuous through transabdominal port system or...

10.3390/life12091351 article EN cc-by Life 2022-08-30

6 Background: Adjacent ductal carcinoma in situ (DCIS) is found approximately 45% of invasive carcinomas (IDC) the breast. Pure DCIS overexpresses HER2 45%. There uncertainty whether adjacent impacts on response to neoadjuvant chemotherapy and trastuzumab as well expression IDC component or changes throughout treatment. Methods: Core biopsies surgical tissue from participants GeparQuattro study with HER2-positive were centrally examined for area before after receiving...

10.1200/jco.2011.29.27_suppl.6 article EN Journal of Clinical Oncology 2011-09-20

10.1007/bf02456591 article DE Journal of Neurology 1898-12-01
Coming Soon ...